(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch - 2Fake new headlights rule steer Australian drivers astray
- 3Which European palace do you fantasy about visiting? Vote!
- 4UN mission says no evidence Hezbollah rearming in southern Lebanon
- 5November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- Must-Sit in front of the Programs from Europe and the US
- Virtual reality opens doors for older people to build closer connections in real life
- We tasted one of the 10,000 Hershey's Dubai chocolate bars being resold on eBay. Is it worth the hype?
- Believe Should Unwind? Look at These Scaled down Games
- Financial plan Cordial Home Redesigns That Add Worth
- Scientists are getting our robotic explorers ready to help send humans to Mars
- EU foreign ministers commemorate Russian massacre in Bucha
- Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
- The 10 Most Progressive Logical Disclosures
